Divergent effects of prostaglandin receptor signaling on neuronal survival

Neuroscience Letters

Volumn 421, Issue 3, 2007, Pages 253-258

  Wu, Liejun ^b   Wang, Qian ^a   Liang, Xibin ^a   Andreasson, Katrin ^a  

^a STANFORD UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ALS; Excitotoxicity; Inflammation; Lipopolysaccharide; Neuroprotection; Organotypic culture; Prostaglandin; Receptor

Indexed keywords

PROSTACYCLIN RECEPTOR; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN F2 ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR; THROMBOXANE A2 RECEPTOR; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; EXCITOTOXICITY; HIPPOCAMPUS; INFLAMMATION; MOTONEURON; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; SPINAL CORD;

ANIMALS; ANIMALS, NEWBORN; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; HIPPOCAMPUS; HYDANTOINS; MICE; MICE, INBRED C57BL; NEURONS; NOOTROPIC AGENTS; ORGAN CULTURE TECHNIQUES; PROSTAGLANDIN D2; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION; SPINAL CORD; TACRINE; TIME FACTORS;

EID: 34250620551     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.05.055     Document Type: Article

References (24)

1. Almer G., Guegan C., Teismann P., Naini A., Rosoklija G., Hays A.P., Chen C., and Przedborski S. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann. Neurol. 49 (2001) 176-185
2. Andreasson K.I., Savonenko A., Vidensky S., Goellner J.J., Zhang Y., Shaffer A., Kaufmann W.E., Worley P.F., Isakson P., and Markowska A.L. Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J. Neurosci. 21 (2001) 8198-8209
3. Bilak M., Wu L., Wang Q., Haughey N., Conant K., St Hillaire C., and Andreasson K. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann. Neurol. 56 (2004) 240-248
4. Bosetti F. Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models. J. Neurochem. (2007)
5. Breyer R.M., Bagdassarian C.K., Myers S.A., and Breyer M.D. Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 661-690
6. Chen C., Magee J.C., and Bazan N.G. Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity. J. Neurophysiol. 87 (2002) 2851-2857
7. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., and Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 52 (2002) 771-778
8. Drachman D.B., and Rothstein J.D. Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann. Neurol. 48 (2000) 792-795
9. Hewett S.J., Bell S.C., and Hewett J.A. Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system. Pharmacol. Ther. 112 (2006) 335-357
10. Hoozemans J.J., and O'Banion M.K. The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr. Drug Targets 4 (2005) 307-315
11. Kawano T., Anrather J., Zhou P., Park L., Wang G., Frys K.A., Kunz A., Cho S., Orio M., and Iadecola C. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat. Med. 12 (2006) 225-229
12. Kiriyama M., Ushikubi F., Kobayashi T., Hirata M., Sugimoto Y., and Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 122 (1997) 217-224
13. Liang X., Wang Q., Hand T., Wu L., Breyer R.M., Montine T.J., and Andreasson K. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J. Neurosci. 25 (2005) 10180-10187
14. Liang X., Wu L., Hand T., and Andreasson K. Prostaglandin D2 mediates neuronal protection via the DP1 receptor. J. Neurochem. 92 (2005) 477-486
15. Liu D., Wu L., Breyer R., Mattson M.P., and Andreasson K. Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann. Neurol. 57 (2005) 758-761
16. McCullough L., Wu L., Haughey N., Liang X., Hand T., Wang Q., Breyer R.M., and Andreasson K. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J. Neurosci. 24 (2004) 257-268
17. Milatovic D., Zaja-Milatovic S., Montine K.S., Shie F.S., and Montine T.J. Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immune response in vivo. J. Neuroinflammation 1 (2004) 20
18. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol. 18 (2005) 315-321
19. Montine T.J., Milatovic D., Gupta R.C., Valyi-Nagy T., Morrow J.D., and Breyer R.M. Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J. Neurochem. 83 (2002) 463-470
20. Shie F.S., Montine K.S., Breyer R.M., and Montine T.J. Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia 52 (2005) 70-77
21. Taniguchi H., Mohri I., Okabe-Arahori H., Aritake K., Wada K., Kanekiyo T., Narumiya S., Nakayama M., Ozono K., Urade Y., and Taniike M. Prostaglandin D2 protects neonatal mouse brain from hypoxic ischemic injury. J. Neurosci. 27 (2007) 4303-4312
22. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., and Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 5473-5478
23. Yamagata K., Andreasson K., Kaufmann W.E., Barnes C.A., and Worley P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11 (1993) 371-386
24. Yasojima K., Tourtellotte W.W., McGeer E.G., and McGeer P.L. Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology 57 (2001) 952-956